ARMATA PHARMACEUTICALS, INC. (ARMP) Operating Margin
- Operating margin · 12 months: Value (m); Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | (m) | Operating income / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | -40.70M USD | Operating Income (Loss) |
| Revenue | (m) | |
| Cost of products and services | (m) | |
| Research and development | (m) | Research and Development Expense |
| Selling, general and administration | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $-40.70M | (m) | (m) | (m) | (m) | (m) |
| 2026-03-31 | $-37.23M | (m) | (m) | (m) | (m) | (m) |
| 2025-12-31 | $-36.63M | (m) | (m) | (m) | (m) | (m) |
| 2025-09-30 | $-33.35M | (m) | (m) | (m) | (m) | (m) |
| 2025-06-30 | $-35.33M | (m) | (m) | (m) | (m) | (m) |
| 2025-03-31 | $-40.40M | (m) | (m) | (m) | (m) | (m) |
| 2024-12-31 | $-42.44M | (m) | (m) | (m) | (m) | (m) |
| 2024-09-30 | $-41.48M | (m) | (m) | (m) | (m) | (m) |
| 2024-06-30 | $-42.06M | (m) | (m) | (m) | (m) | (m) |
| 2024-03-31 | $-39.77M | (m) | (m) | (m) | (m) | (m) |
| 2023-12-31 | $-40.89M | (m) | (m) | (m) | (m) | (m) |
| 2023-09-30 | $-41.64M | (m) | (m) | (m) | (m) | (m) |
| 2023-06-30 | $-39.93M | (m) | (m) | (m) | (m) | (m) |
| 2023-03-31 | $-39.52M | (m) | (m) | (m) | (m) | (m) |
| 2022-12-31 | $-36.95M | (m) | (m) | (m) | (m) | (m) |
| 2022-09-30 | $-32.67M | (m) | (m) | (m) | (m) | (m) |
| 2022-06-30 | $-30.19M | (m) | (m) | (m) | (m) | (m) |
| 2022-03-31 | $-27.16M | (m) | (m) | (m) | (m) | (m) |
| 2021-12-31 | $-23.82M | (m) | (m) | (m) | (m) | (m) |
| 2021-09-30 | $-24.23M | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | $-23.71M | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | $-22.10M | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | $-21.59M | (m) | (m) | (m) | (m) | (m) |
| 2020-09-30 | $-19.51M | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | $-20.66M | (m) | (m) | (m) | (m) | (m) |
| 2020-03-31 | $-21.23M | (m) | (m) | (m) | (m) | (m) |
| 2019-12-31 | $-19.75M | (m) | (m) | $9.82M | (m) | (m) |
| 2019-09-30 | $-13.04M | (m) | (m) | (m) | (m) | (m) |
| 2019-06-30 | $-8.69M | (m) | (m) | (m) | (m) | (m) |
| 2019-03-31 | $-13.07M | (m) | (m) | $4.92M | (m) | (m) |
| 2018-12-31 | $-12.52M | (m) | (m) | $4.89M | (m) | (m) |
| 2018-09-30 | $-10.11M | (m) | (m) | $4.61M | (m) | (m) |
| 2018-06-30 | $-9.22M | (m) | (m) | $3.42M | (m) | (m) |
| 2018-03-31 | $-15.85M | (m) | (m) | $2.85M | (m) | (m) |
| 2017-12-31 | $-16.16M | (m) | (m) | $2.88M | (m) | (m) |
| 2017-09-30 | $-25.66M | (m) | (m) | (m) | (m) | (m) |
| 2017-06-30 | $-28.32M | (m) | (m) | $5.08M | (m) | (m) |
| 2017-03-31 | $-22.22M | (m) | (m) | $5.19M | (m) | (m) |
| 2016-12-31 | $-23.38M | (m) | (m) | $5.68M | (m) | (m) |
| 2016-09-30 | $-14.45M | (m) | (m) | $6.09M | (m) | (m) |
| 2016-06-30 | $-13.47M | (m) | (m) | $5.16M | (m) | (m) |
| 2016-03-31 | $-12.48M | (m) | (m) | $5.00M | (m) | (m) |
| 2015-12-31 | $-10.23M | (m) | (m) | $3.99M | (m) | (m) |
| 2015-09-30 | $-9.88M | (m) | (m) | $3.89M | (m) | (m) |
| 2015-06-30 | $-12.69M | (m) | (m) | $4.96M | (m) | (m) |
| 2015-03-31 | $-13.84M | (m) | (m) | $5.77M | (m) | (m) |
| 2014-12-31 | $-14.11M | (m) | (m) | $5.80M | (m) | (m) |
| 2014-09-30 | $-13.90M | (m) | (m) | $5.81M | (m) | (m) |
| 2014-06-30 | $-11.28M | (m) | (m) | $5.11M | (m) | (m) |
| 2014-03-31 | $-13.81M | (m) | (m) | $6.96M | (m) | (m) |
| 2013-12-31 | $-12.44M | (m) | (m) | $6.50M | (m) | (m) |
| 2013-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |